SCHEMBL11999151

SCHEMBL11999151

CC(C)(C)c1ccc(C(Cc2ccc(C(=O)NCCS(=O)(=O)O)cc2)C(=O)NC(c2ccccc2)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 12/20 0.55
ADCY6 O43306 6/20 0.55
ADCY3 O60266 6/20 0.55
ADCY9 O60503 6/20 0.55
ADCY5 O95622 6/20 0.55
ADCY8 P40145 6/20 0.55
ADCY7 P51828 6/20 0.55
ADCY2 Q08462 6/20 0.55
ADCY1 Q08828 6/20 0.55
ADCY4 Q8NFM4 6/20 0.55
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
ESRRG P62508 1/20 0.47
LMNA P02545 1/20 0.44
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
POLB P06746 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
OPRK1 P41145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16152647 0.90 GCGR (0.44) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL12001866 0.85 GCGR (0.74) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL21287238 0.85 GCGR (0.74) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11999202 0.84 GCGR (0.78) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11999153 0.84 GCGR (0.69) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL15695488 0.84 GCGR (0.52) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11999152 0.82 GCGR (0.56) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL12001887 0.82 GCGR (0.72) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11999154 0.81 GCGR (0.65) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL12002035 0.81 GCGR (0.62) GCGRADCY6ADCY3ADCY9ADCY5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 US disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 563/4885ADCY3 335/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 723/4885ADCY3 398/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 703/4885ADCY3 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.